Daon receives FIDO certification for IdentityX Mobile Authentication Platform

NewsGuard 100/100 Score

Daon, a global leader in mobile biometric authentication technology, announced today that its IdentityX Mobile Authentication Platform v4.0 has been FIDO Certified. The FIDO (Fast IDentity Online) Alliance is an industry consortium launched in 2013 to revolutionize online security with open standards for simpler, stronger authentication. In order to receive certification, a company's products and services must pass a rigorous series of tests that measure compliance and ensure interoperability among other products and services that support FIDO 1.0 specifications.

"We are very pleased to have received this certification," commented Conor White, President, Daon. "Our goal is to eliminate the public's dependence on antiquated passwords by providing a faster, more flexible, and inherently more secure authentication solution through biometrics. The FIDO alliance plays an important role in helping to promote the adoption of strong authentication products and services by governments, private business and consumers and we are delighted to add FIDO to the many ways our customers can authenticate through the IdentityX platform."

"Daon has been an active supporter of the FIDO Alliance and its mission," said Brett McDowell, executive director, FIDO Alliance. "The FIDO Certified program offers the type of oversight that industry needs to hasten the adoption of strong authentication products and services that stretch across enterprise boundaries and the range of mobile and other devices key in today's computing environment."

FIDO certification is performed using a set of test tools developed by the FIDO Alliance, followed by participation in a proctored interoperability event. The FIDO Certified testing complements the previous FIDO Ready™ program.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New vaccine promises broad protection against SARS-CoV-2 and other sarbecoviruses